Patent · US Active

Rationally designed antibodies

US8771932B2 · kind B2 · utility

1Cited by

35References

20Claims

0Family size

Assignee

Alexion Pharmaceuticals, Inc. · US

Inventors

Katherine S. Bowdish · Del Mar, US
Mark Renshaw · San Diego, US
Shana Frederickson · Solana Beach, US

Key dates

Filing date	Jan 26, 2009
Grant date	Jul 8, 2014
Priority date	—
Expiry date	Sep 7, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/11
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.